Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Slasor

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Molecular Genetics and Metabolism|March 5, 2013
The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjectsPaul Harmatz, Karl Eugen Mengel, Roberto Giugliani, et al.
The Lancet. Neurology|December 15, 2023
Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension studyAngela Schulz, Nicola Specchio, Emily de Los Reyes, et al.
Molecular Genetics and Metabolism|July 7, 2016
Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndromeChristian J Hendriksz, Rossella Parini, Moeenaldeen D AlSayed, et al.
Molecular Genetics and Metabolism|January 14, 2015
Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndromePaul R Harmatz, Karl Eugen Mengel, Roberto Giugliani, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Molecular Genetics and Metabolism|March 5, 2013
The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjectsPaul Harmatz, Karl Eugen Mengel, Roberto Giugliani, et al.
The Lancet. Neurology|December 15, 2023
Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension studyAngela Schulz, Nicola Specchio, Emily de Los Reyes, et al.
Molecular Genetics and Metabolism|July 7, 2016
Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndromeChristian J Hendriksz, Rossella Parini, Moeenaldeen D AlSayed, et al.
Molecular Genetics and Metabolism|January 14, 2015
Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndromePaul R Harmatz, Karl Eugen Mengel, Roberto Giugliani, et al.
Pageof 2